International Assets Investment Management LLC Has $577,000 Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

International Assets Investment Management LLC grew its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 29,580.0% in the third quarter, Holdings Channel reports. The institutional investor owned 10,388 shares of the biopharmaceutical company’s stock after purchasing an additional 10,353 shares during the period. International Assets Investment Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $577,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. nVerses Capital LLC raised its position in shares of Ultragenyx Pharmaceutical by 237.5% during the third quarter. nVerses Capital LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 1,900 shares during the last quarter. CWM LLC raised its position in shares of Ultragenyx Pharmaceutical by 9,552.5% during the third quarter. CWM LLC now owns 21,332 shares of the biopharmaceutical company’s stock valued at $1,185,000 after buying an additional 21,111 shares during the last quarter. Handelsbanken Fonder AB raised its position in Ultragenyx Pharmaceutical by 15.0% in the third quarter. Handelsbanken Fonder AB now owns 24,523 shares of the biopharmaceutical company’s stock worth $1,362,000 after purchasing an additional 3,200 shares in the last quarter. Maven Securities LTD raised its position in Ultragenyx Pharmaceutical by 100.0% in the second quarter. Maven Securities LTD now owns 20,000 shares of the biopharmaceutical company’s stock worth $822,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Clearline Capital LP acquired a new position in Ultragenyx Pharmaceutical in the second quarter worth about $1,355,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Activity

In other news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CFO Howard Horn sold 7,465 shares of the stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the sale, the chief financial officer now directly owns 92,301 shares of the company’s stock, valued at $4,869,800.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,556 shares of company stock valued at $1,515,967 over the last three months. 5.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

RARE has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $116.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, October 22nd. The Goldman Sachs Group increased their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Barclays dropped their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Wells Fargo & Company increased their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $85.17.

Ultragenyx Pharmaceutical Trading Up 2.2 %

Shares of Ultragenyx Pharmaceutical stock opened at $52.18 on Wednesday. The stock has a market capitalization of $4.81 billion, a price-to-earnings ratio of -7.15 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a 1-year low of $34.06 and a 1-year high of $60.37. The firm’s 50-day moving average price is $55.47 and its two-hundred day moving average price is $48.09.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.